Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Making lawyers swear Oath of Allegiance to monarch unconstitutional: Alberta court

December 17, 2025

Toronto mayor says Eglinton Crosstown LRT won’t open within next month

December 17, 2025

U.S. may soon reclassify marijuana to allow medical research. What to know

December 17, 2025

Amazon has a new leader for its ‘AGI’ group as it plays catch-up on AI

December 17, 2025

Bitget Wallet Launches Rewards Hub for Onchain Tasks and Programs

December 17, 2025
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » U.S. IVD And LDT For Autoimmune Diseases Market Research 2024-2030: Rising Awareness of Autoimmune Disorders Fuels Demand for Innovative Diagnostic Solutions
Press Release

U.S. IVD And LDT For Autoimmune Diseases Market Research 2024-2030: Rising Awareness of Autoimmune Disorders Fuels Demand for Innovative Diagnostic Solutions

By News RoomSeptember 24, 20245 Mins Read
U.S. IVD And LDT For Autoimmune Diseases Market Research 2024-2030: Rising Awareness of Autoimmune Disorders Fuels Demand for Innovative Diagnostic Solutions
Share
Facebook Twitter LinkedIn Pinterest Email
U.S. IVD And LDT For Autoimmune Diseases Market Research 2024-2030: Rising Awareness of Autoimmune Disorders Fuels Demand for Innovative Diagnostic Solutions

Dublin, Sept. 24, 2024 (GLOBE NEWSWIRE) — The “U.S. IVD And LDT For Autoimmune Diseases Market Size, Share & Trends Analysis Report By Type (IVD, LDT), By Technology (Immunoassays, Clinical Chemistry, Hematology, Coagulation, Microbiology), By Application, By Country, And Segment Forecasts, 2024 – 2030” report has been added to ResearchAndMarkets.com’s offering.

The U.S. IVD and LDT for autoimmune diseases market size is expected to reach USD 3.70 billion by 2030, growing at a CAGR of 4.8% from 2024 to 2030

The high prevalence of autoimmune disorders, growing awareness about these ailments, growing demand for technologically developed & high performance products, and high investments in research are the driving factors for the expanding growth of the market.

These health problems are second leading cause of chronic illness in the U.S. and are amongst the leading causes of deaths in the U.S. women. They have an adverse impact on the work productivity and the quality of life of patients and form an economic burden greatly affecting the healthcare spending in the U.S. The National Institute of Health estimates the direct healthcare costs associated with these disorders accounted for around USD 100 billion, whereas the cancer costs accounted for USD 57 billion.

A large number of people suffering from these disorders and rising prevalence at an alarming rate resulting in an increase of healthcare spending in the U.S. are all priority concerns, and is thus are expected to drive growth. Furthermore, the complications resulting from such health hazards like damage to internal organs, loss of mobility, and risk of death make it crucial for early diagnosis and intervention of such conditions. The rising awareness about these conditions is expected to lead market growth.

It is believed by number of researchers that the increase in the number of autoimmune diseases globally is due to the genetic predisposition and environmental factors. But there is very little knowledge about what exactly in the environment triggers the occurrence of autoimmune diseases. and mainly focused on commercial kits that are widely used by laboratories.

The FDA regulates IVD as medical devices however in the past it did not use its authority to regulate LDT. The FDA later announced that it would enforce its medical device regulatory authority to regulate the LDTs. Some researchers believe that the FDA regulation on LDTs would lead to an increase in the time and cost required to develop the tests.

U.S. IVD And LDT For Autoimmune Diseases Market Report Highlights

  • In 2023, the IVD for rheumatoid arthritis was the leading segment with a revenue share of 12.14% and the LDT for rheumatoid arthritis had a share of 11.47%. The large number of diagnostic tests available for it as well as the high prevalence of the disease contributed to the market share.
  • In 2023, clinical chemistry was the leading segment with a market share of 32.37% in the IVD and 19.98% in the LDT. The diagnosis of autoantibodies in the blood is the most commonly employed diagnosis, thus contributing to the large share.
  • Crohn’s disease is projected to grow at the fastest CAGR over the forecast period

Companies Featured

  • Adaptive Biotechnologies Corporation;
  • Agilent Technologies Inc.
  • Bio-Rad Laboratories, Inc.
  • bioMerieux, Inc.
  • Corgenix, Inc.
  • Johnson & Johnson Services, Inc.
  • Microbix Biosystems Inc.
  • PerkinElmer, Inc.
  • SQI Diagnostics Inc.
  • Thermo Fisher Scientific Inc.

Key Attributes:

Report Attribute Details
No. of Pages 100
Forecast Period 2023 – 2030
Estimated Market Value (USD) in 2023 $2.67 Billion
Forecasted Market Value (USD) by 2030 $3.7 Billion
Compound Annual Growth Rate 4.8%
Regions Covered United States

Key Topics Covered:

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. U.S. IVD & LDT for Autoimmune Diseases Market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Billion)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. U.S. IVD & LDT for Autoimmune Diseases Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.2. PESTEL Analysis

Chapter 4. U.S. IVD & LDT for Autoimmune Diseases Market: Type Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. U.S. IVD & LDT for Autoimmune Diseases Market: Type Movement Analysis, 2023 & 2030 (USD Billion)
4.3. IVD
4.4. LDT

Chapter 5. U.S. IVD & LDT for Autoimmune Diseases Market: Technology Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. U.S. IVD & LDT for Autoimmune Diseases Market: Technology Movement Analysis, 2023 & 2030 (USD Billion)
5.3. Immunoassays
5.4. Clinical Chemistry
5.5. Hematology
5.6. Coagulation
5.7. Microbiology
5.8. Molecular Diagnostics
5.9. Other

Chapter 6. U.S. IVD & LDT for Autoimmune Diseases Market: Application Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. U.S. IVD & LDT for Autoimmune Diseases Market: Application Movement Analysis, 2023 & 2030 (USD Billion)
6.3. Addison’s Disease
6.4. Ankylosing Spondylitis
6.5. Alopecia Areata
6.6. Rheumatoid Arthritis
6.7. Systemic Lupus Erythematosus
6.8. Systemic Sclerosis
6.9. Psoriasis
6.10. Antiphospholipid Antibody Syndrome
6.11. Diabetes Type 1
6.12. Crohn’s Disease
6.13. Ulcerative Colitis
6.14. Narcolepsy
6.15. Multiple Sclerosis
6.16. Uveitis

Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis by Key Market Participants
7.2. Company Categorization
7.3. Company Heat Map Analysis
7.4. Company Profiles
7.4.1. Participant’s Overview
7.4.2. Financial Performance
7.4.3. Product Benchmarking
7.4.4. Recent Developments/ Strategic Initiatives

For more information about this report visit https://www.researchandmarkets.com/r/o94l6x

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

  • U.S. IVD And LDT For Autoimmune Diseases Market

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

Bitget Wallet Launches Rewards Hub for Onchain Tasks and Programs

Coder and GlobalLogic Partner to Accelerate AI Development in the Enterprise

PyroGenesis Signs Contract Toward the Use of Plasma in the Treatment of Low-Level Radioactive Waste

When Holiday Cheer Turns to Holiday Stress: A Look at the Mind Behind Seasonal Emotions

SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D

Gabelli Funds Now Offers Seven Fully Transparent ETF Strategies

SAGA Metals Defines Key Structural Geology at Trapper South & Provides Corporate Update

The 2026 State of Performance Marketing Report: How Inflated Signals, AI Noise, and Disconnected Tools Are Derailing B2B Growth

HAProxy Technologies Announces Availability of HAProxy Community Performance Packages Compiled with AWS-LC

Editors Picks

Toronto mayor says Eglinton Crosstown LRT won’t open within next month

December 17, 2025

U.S. may soon reclassify marijuana to allow medical research. What to know

December 17, 2025

Amazon has a new leader for its ‘AGI’ group as it plays catch-up on AI

December 17, 2025

Bitget Wallet Launches Rewards Hub for Onchain Tasks and Programs

December 17, 2025

Subscribe to News

Get the latest Canada news and updates directly to your inbox.

Latest News

Coder and GlobalLogic Partner to Accelerate AI Development in the Enterprise

December 17, 2025

PyroGenesis Signs Contract Toward the Use of Plasma in the Treatment of Low-Level Radioactive Waste

December 17, 2025

When Holiday Cheer Turns to Holiday Stress: A Look at the Mind Behind Seasonal Emotions

December 17, 2025
Facebook X (Twitter) Pinterest TikTok Instagram
© 2025 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version